Tisdag 26 November | 07:54:40 Europe / Stockholm
Svenska | English
Investor Relations
Public Relations

Xintela AB

Bifogade filer

Kursutveckling under dagen för detta pressmeddelande (SEK).

Likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

Tid*
2025-02-28 07:00 Bokslutskommuniké 2024
2024-11-22 - Kvartalsrapport 2024-Q3
2024-08-30 - Kvartalsrapport 2024-Q2
2024-05-24 - Kvartalsrapport 2024-Q1
2024-05-10 - X-dag ordinarie utdelning XINT 0.00 SEK
2024-05-08 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-24 - Kvartalsrapport 2023-Q3
2023-08-30 - Kvartalsrapport 2023-Q2
2023-05-25 - Kvartalsrapport 2023-Q1
2023-05-15 - X-dag ordinarie utdelning XINT 0.00 SEK
2023-05-12 - Årsstämma
2023-02-24 - Bokslutskommuniké 2022
2022-11-28 - Extra Bolagsstämma 2022
2022-11-25 - Kvartalsrapport 2022-Q3
2022-08-26 - Kvartalsrapport 2022-Q2
2022-05-20 - Kvartalsrapport 2022-Q1
2022-05-09 - X-dag ordinarie utdelning XINT 0.00 SEK
2022-05-06 - Årsstämma
2022-02-25 - Bokslutskommuniké 2021
2021-11-19 - Kvartalsrapport 2021-Q3
2021-08-27 - Kvartalsrapport 2021-Q2
2021-07-05 - Extra Bolagsstämma 2021
2021-05-21 - Kvartalsrapport 2021-Q1
2021-05-10 - X-dag ordinarie utdelning XINT 0.00 SEK
2021-05-07 - Årsstämma
2021-02-26 - Bokslutskommuniké 2020
2020-11-27 - Kvartalsrapport 2020-Q3
2020-08-28 - Kvartalsrapport 2020-Q2
2020-06-10 - X-dag ordinarie utdelning XINT 0.00 SEK
2020-06-09 - Årsstämma
2020-05-29 - Kvartalsrapport 2020-Q1
2020-02-28 - Bokslutskommuniké 2019
2019-11-29 - Kvartalsrapport 2019-Q3
2019-08-30 - Kvartalsrapport 2019-Q2
2019-05-28 - X-dag ordinarie utdelning XINT 0.00 SEK
2019-05-27 - Årsstämma
2019-05-23 - Kvartalsrapport 2019-Q1
2019-02-27 - Bokslutskommuniké 2018
2018-11-28 - Kvartalsrapport 2018-Q3
2018-09-21 - Extra Bolagsstämma 2018
2018-08-29 - Kvartalsrapport 2018-Q2
2018-05-30 - X-dag ordinarie utdelning XINT 0.00 SEK
2018-05-29 - Årsstämma
2018-05-25 - Kvartalsrapport 2018-Q1
2018-02-22 - Bokslutskommuniké 2017
2017-11-23 - Kvartalsrapport 2017-Q3
2017-08-30 - Kvartalsrapport 2017-Q2
2017-05-19 - X-dag ordinarie utdelning XINT 0.00 SEK
2017-05-18 - Årsstämma
2017-05-18 - Kvartalsrapport 2017-Q1
2017-02-28 - Bokslutskommuniké 2016
2016-11-23 - Kvartalsrapport 2016-Q3
2016-08-24 - Kvartalsrapport 2016-Q2
2016-05-31 - X-dag ordinarie utdelning XINT 0.00 SEK
2016-05-30 - Årsstämma
2016-04-26 - Bokslutskommuniké 2015

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Xintela är verksamt inom bioteknik. Bolagets kompetens återfinns inom regenerativ medicin, samt behandling av cancer, ledbroskskador samt hjärntumörer. Forskningen baseras på utvecklandet av proteinmolekyler som har kapacitet att känna av förändringar på cellers yta, vilket möjliggör identifiering av de stamceller som är på väg att utvecklas till broskceller. Bolaget grundades under 2009 och har sitt huvudkontor i Lund.
Xintela AB Interim Report January - September 2023
2023-11-24 08:00:00

Summary of the interim report
The “Company” or “Xintela” refers to Xintela AB (publ), corporate registration number 556780-3480.

Third quarter 2023 for the group
Income amounted to TSEK 0 (0).
Loss before tax totalled TSEK 11,953 (loss: 14,456).
Loss per share was SEK 0.02 (loss: 0.11).

First nine month 2023 for the group
Income amounted to TSEK 0 (0).
Loss before and tax totalled TSEK 46,192 (loss: 49,781).
Loss per share was SEK 0,11 (loss: 0,36)

Third quarter 2023 for the parent company
Income amounted to TSEK 0 (0).
Loss before tax totalled TSEK 8,916 (loss: 9,197).
Loss per share was SEK 0.02 (loss: 0.07).

First nine month 2023 for the parent company
Income amounted to TSEK 0 (0).
Loss before tax totalled TSEK 30,469 (loss: 31,786).
Loss per share was SEK 0,08 (loss: 0,23).
At September 30, 2023, the equity/assets ratio was 82 % (59).

Significant events in the third quarter of 2023
Xintela publishes the outcome of the rights issue. (July 4, 2023)
Xintela gets product patent in USA for chondrocyte-based products. (August 15, 2023)

Significant events after the end of the period
Xintela’s stem cell product, XSTEM, has been assessed as safe at all dose levels in knee osteoarthritis clinical study. (October 10, 2023)

The complete report is available for download below and on the company’s website www.xintela.se/en/investors#reports.

Contacts

Xintela AB (publ)
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
Email: evy@xintela.se
Medicon Village
223 81 Lund, Sweden
www.xintela.se

About Xintela

Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma. Xintela conducts its business at Medicon Village in Lund, Sweden, and is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB.

Attachments

Xintela 2023 Q3 EN

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden